Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
Glioblastoma multiforme (GBM) is the most common and malignant brain tumor, and almost half of the patients carrying EGFR-driven tumor with PTEN deficiency are resistant to EGFR-targeted therapy. EGFR amplification and/or mutation is reported in various epithelial tumors. This series of studies aime...
Guardado en:
Autores principales: | Kunyan He, Guang-Xing Wang, Li-Nan Zhao, Xiao-Fang Cui, Xian-Bin Su, Yi Shi, Tian-Pei Xie, Shang-Wei Hou, Ze-Guang Han |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cebf564c4d7442b68cbe99b6f2dd17bc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cinobufagin Exerts Anticancer Activity in Oral Squamous Cell Carcinoma Cells through Downregulation of ANO1
por: Sungwoo Jo, et al.
Publicado: (2021) -
Lamellipodin-RICTOR Signaling Mediates Glioblastoma Cell Invasion and Radiosensitivity Downstream of EGFR
por: Stefanie Moritz, et al.
Publicado: (2021) -
Rol patogénico del gen supresor de tumores PTEN en cáncer ovárico asociado a endometriosis
por: Castiblanco G,Adriana, et al.
Publicado: (2006) -
circPTEN suppresses colorectal cancer progression through regulating PTEN/AKT pathway
por: Chen Li, et al.
Publicado: (2021) -
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Yurong Wang, et al.
Publicado: (2021)